Liver function study aims to understand drug processing
NCT ID NCT07343960
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study looks at how the drug capivasertib is processed by the body in people with moderate liver impairment compared to those with normal liver function. About 20 participants will receive a single dose and have their blood levels measured. The goal is to understand safety and dosing, not to treat the liver condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGRialto, California, 92377, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.